Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvon Protection Regulatory News (AVON)

Share Price Information for Avon Protection (AVON)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,320.00
Bid: 1,320.00
Ask: 1,332.00
Change: -22.00 (-1.64%)
Spread: 12.00 (0.909%)
Open: 1,370.00
High: 1,370.00
Low: 1,320.00
Prev. Close: 1,342.00
AVON Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Post Close Half Year Trading Update

6 Apr 2022 07:00

RNS Number : 3970H
Avon Protection PLC
06 April 2022
 

6 April 2022

Avon Protection plc

Post Close Half Year Trading Update

 

Avon Protection plc ("Avon Protection" or "the Group") today provides the following trading update for the six months ended 31 March 2022 ("HY22" or the "Period"). Unless otherwise stated, figures and commentary exclude the armor business.

 

Trading update

 

Trading in the first half reflects a continuation of some of the challenges seen in FY21, but with performance accelerating through the second quarter. Order intake was, as expected, lower than the comparable period last year reflecting a very strong first half in 2021, but, following the events in Ukraine, enquiries remain robust giving us confidence in order intake for the second half and beyond. Revenue for the Period was in line with expectations and ahead overall by c. 4%, with organic year-on-year performance broadly flat.

 

Profitability has however been impacted, in broadly even proportions, by a weaker than expected sales mix in the first half and additional manufacturing costs, notably in the helmets business, due to supply chain and process inefficiencies. As a result, the adjusted EBITDA margin for the period is expected to be approximately 10%.

 

Operationally, we have made good progress on the implementation of the $15m overhead cost saving programme announced in December 2021 (of which approximately half relates to overheads in the armor business and the remainder relates to the rest of the Group), including the closure of one of our U.S. offices and a change in management structure which streamlines the organisation into one focussed business.

 

Strategically, we are pleased with our continued progress, which includes the award of the U.S. DLA contract for the second-generation Advanced Combat Helmet in February and delivery of the next-generation Integrated Head Protection System for first article test scheduled for Q3. This momentum further reinforces our position as a leading provider of head protection to the U.S. military and provides a strong platform for future growth.

 

Outlook

 

The recent events in Ukraine have highlighted the criticality of our products and capabilities, and we have seen a notable increase in customer enquiry activity.

 

We have a number of active discussions ongoing with customers regarding potential incremental orders across both respiratory and helmet products. While these discussions remain ongoing and the quantum and timing of resultant orders are still to be determined, the impact of this growth in demand is most likely to be seen in FY23 and beyond, and as such the Board continues to have a range of expected full year revenue outcomes for FY22 consistent with market expectations.

 

Profitability in H2 is expected to improve versus H1 but will not offset the weakness experienced in the Period. Full year underlying earnings will therefore be lower than previously expected.

 

The second half margin will benefit from the adverse mix impact substantially unwinding along with the operational gearing effect of higher revenues and the initial contribution from the cost saving initiatives. The manufacturing inefficiencies described above are expected to improve as higher volumes are achieved. As a result, the Board expects EBITDA margins to recover progressively through the second half of the financial year and beyond, with the extent of this improvement in part dependent on the quantum and timing of incremental orders. Looking forward into FY23, the Group's profitability will benefit from the improved FY22 exit run-rate and the full year effect of the cost savings.

 

Armor business

 

In the period, as expected, armor revenues were in the low single digit $m pending final sign-off of first article testing of the DLA ESAPI body armor product. Combined with overheads, this business therefore operated at an EBITDA loss in the first half. We have continued with our steps for an orderly exit of this business once existing contracts are satisfied.

 

Commenting, Paul McDonald, Chief Executive Officer, said:

"At Avon Protection, our purpose is to protect people and save lives. As a global leader in military-grade respiratory and head protection, we are seeing an increased demand for our products for both the short and longer term. We are working proactively with our key customers to confirm their requirements and maximise our available capacity in the short term. Longer term, this will create further opportunities and will likely result in mid-term capacity expansion to meet expected demand."

 

 

Notice of Results

The Group will release its results for the half year ended 31 March 2022 on 24 May 2022.

 

For further enquiries, please contact:

 

Avon Protection plc

Paul McDonald, Chief Executive Officer

01225 896 848

Rich Cashin, Chief Financial Officer

Rachel Stevens, Director of Investor Relations

MHP Communications

Andrew Jaques

0203 128 8570

Charlie Barker

avonprotection@mhpc.com

Pete Lambie

 

Legal Entity Identifier: 213800JM1AN62REBWA71

Certain information contained in this announcement would have constituted inside information (as defined by Article 7 of Regulation (EU) No 596/2014) ("MAR") prior to its release as part of this announcement and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations.

Note to editors: 

Avon Protection designs and produces life critical personal protection solutions for the world's militaries and first responders. With a portfolio that includes Chemical, Biological, Radiological, Nuclear ("CBRN"), respiratory and head protection products, Avon Protection's mission is to relentlessly advance the future of protection enhancing the performance, efficiency and capability of their customers whilst providing ever increasing levels of protection.

Avon Protection operates from six locations employing approximately 1,000 people and is listed on the London Stock Exchange (LSE: AVON).

For further information, please visit our website www.avon-protection-plc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFFSISLIEIIF
Date   Source Headline
21st Jan 20165:19 pmRNSHolding(s) in Company
21st Jan 20164:29 pmRNSDirector/PDMR Shareholding
5th Jan 20163:10 pmRNSDirector/PDMR Shareholding
15th Dec 20155:31 pmRNSHolding(s) in Company
14th Dec 201510:38 amRNSDirectorate Change
7th Dec 20155:04 pmRNSDirector/PDMR Shareholding
4th Dec 20155:42 pmRNSAnnual Financial Report
2nd Dec 201512:04 pmRNSDirector/PDMR Shareholding
30th Nov 20153:30 pmRNSDirectors' and PDMRs' Interest in Shares
30th Nov 201512:05 pmRNSHolding(s) in Company
30th Nov 20159:06 amRNSHolding(s) in Company
25th Nov 20155:42 pmRNSHolding(s) in Company
23rd Nov 20152:10 pmRNSHolding(s) in Company
20th Nov 201512:29 pmRNSDirector/PDMR Shareholding
19th Nov 20154:51 pmRNSDirector/PDMR Shareholding
17th Nov 20151:00 pmRNSFinal Results
5th Nov 20155:39 pmRNSDirectors'/PDMR Shareholdings
9th Oct 20157:00 amRNSAcquisition
7th Oct 20158:53 amRNSDirector/PDMR Shareholding
6th Oct 20157:00 amRNSPre close trading update
1st Oct 20157:00 amRNSDirectorate Change
8th Sep 20153:26 pmRNSDirector/PDMR Shareholding
2nd Sep 20157:00 amRNSTrading Update
7th Aug 20154:04 pmRNSHolding(s) in Company
6th Aug 20153:35 pmRNSDirector/PDMR Shareholding
6th Aug 20157:00 amRNSAcquisition
8th Jul 20155:34 pmRNSDirector/PDMR Shareholding
29th Jun 20154:27 pmRNSHolding(s) in Company
29th Jun 201511:20 amRNSHolding(s) in Company
22nd Jun 20157:00 amRNSAcquisition
8th Jun 20159:03 amRNSDirector/PDMR Shareholding
1st Jun 20155:01 pmRNSHolding(s) in Company
6th May 20157:02 amRNSDirector/PDMR Shareholding
29th Apr 20157:01 amRNSBoard Change
29th Apr 20157:00 amRNSHalf Yearly Report
8th Apr 20154:24 pmRNSDirector/PDMR Shareholding
26th Mar 201512:22 pmRNSDirector Declaration
5th Mar 20156:30 pmRNSDirector/PDMR Shareholding
25th Feb 201512:24 pmRNSDirectorate Change
17th Feb 20153:55 pmRNSHolding(s) in Company
5th Feb 20153:33 pmRNSDirector/PDMR Shareholding
29th Jan 20151:06 pmRNSResult of AGM and Retirement of Director
29th Jan 20157:00 amRNSAGM Statement
28th Jan 201512:11 pmRNSHolding(s) in Company
20th Jan 201511:50 amRNSDirector/PDMR Shareholding
9th Jan 20153:58 pmRNSDirector/PDMR Shareholding
9th Jan 201510:22 amRNSAnnual Financial Report
6th Jan 20159:42 amRNSDirector/PDMR Shareholding
5th Jan 201512:17 pmRNSDirector/PDMR Shareholding
8th Dec 20145:11 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.